Related Experiment Videos
Regulation of T and B cell responses by modulating interactions between CD28/CTLA4 and their ligands, CD80 and CD86
1Basel Institute for Immunology, Switzerland.
In recent years, it has become clear that the fate of lymphocyte interactions with antigen is determined not only by signals through antigen-specific receptors, but by interactions between pairs of accessory molecules. One such crucial pair of ligands is that between CD80/CD86, expressed by professional APCs and activated T and B cells, and CD28 (resting and activated T cells primarily) and CTLA4 (activated T cells). Signals in this system can amplify (CD28) or inhibit (CTLA4) T cell responses. The uses of soluble competitors for CD28 (CTLA4-Ig) and agonists for the inhibitory receptor CTLA4 (CD80-Ig) offer therapeutic possibilities to tailor autoimmune responses in nonpathogenic directions.
In recent years, it has become clear that the fate of lymphocyte interactions with antigen is determined not only by signals through antigen-specific receptors, but by interactions between pairs of accessory molecules. One such crucial pair of ligands is that between CD80/CD86, expressed by professional APCs and activated T and B cells, and CD28 (resting and activated T cells primarily) and CTLA4 (activated T cells). Signals in this system can amplify (CD28) or inhibit (CTLA4) T cell responses. The uses of soluble competitors for CD28 (CTLA4-Ig) and agonists for the inhibitory receptor CTLA4 (CD80-Ig) offer therapeutic possibilities to tailor autoimmune responses in nonpathogenic directions.